Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gyre Therapeutics Inc (GYRE)

Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,207,356
  • Shares Outstanding, K 93,521
  • Annual Sales, $ 113,450 K
  • Annual Income, $ -92,930 K
  • EBIT $ -157 M
  • EBITDA $ -155 M
  • 60-Month Beta 2.05
  • Price/Sales 10.65
  • Price/Cash Flow 51.94
  • Price/Book 12.26

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 61.26%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 0.00% on 11/18/24
  • IV Low 0.00% on 11/18/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 120
  • Volume Avg (30-Day) 52
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 2,316
  • Open Int (30-Day) 2,305

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.08 +0.58%
on 11/21/24
19.00 -36.05%
on 11/12/24
-2.00 (-14.13%)
since 10/21/24
3-Month
11.38 +6.77%
on 09/05/24
19.00 -36.05%
on 11/12/24
+0.19 (+1.59%)
since 08/21/24
52-Week
8.26 +47.09%
on 08/05/24
30.40 -60.03%
on 12/21/23
-0.58 (-4.56%)
since 11/21/23

Most Recent Stories

More News
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

GYRE : 11.79 (-8.68%)
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

GYRE : 11.79 (-8.68%)
Is It Time to Buy the Nasdaq's 5 Worst-Performing Stocks in February 2024?

Some Nasdaq stocks are soaring in 2024, but these five charts are down by 40% or more. Are any of these struggling stocks actually good buys at a low price?

TCEHY : 52.1800 (-0.44%)
COMP : 6.72 (+4.35%)
$NASX : 18,996.97 (+0.16%)
SGML : 14.61 (+1.04%)
HUT : 23.47 (-4.05%)
GYRE : 11.79 (-8.68%)
GDS : 18.38 (-1.02%)
CIFR : 6.20 (-4.76%)
BTC : 43.67 (+4.37%)
BABA : 85.58 (-1.37%)
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?

These stocks are coming off a banner month, but what about the road ahead?

KRRO : 51.10 (+8.72%)
GYRE : 11.79 (-8.68%)
IXHL : 1.96 (-6.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Gyre Therapeutics Inc. is a biotechnology company. It focused on organ fibrosis and inflammatory diseases. The company's product pipeline primarily includes F573, F528 and F230. Gyre Therapeutics Inc., formerly known as Catalyst Biosciences Inc., is based in United States.

See More

Key Turning Points

3rd Resistance Point 13.58
2nd Resistance Point 13.41
1st Resistance Point 13.16
Last Price 11.79
1st Support Level 12.74
2nd Support Level 12.57
3rd Support Level 12.32

See More

52-Week High 30.40
Fibonacci 61.8% 21.94
Fibonacci 50% 19.33
Fibonacci 38.2% 16.72
Last Price 11.79
52-Week Low 8.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar